Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Athersys ($ATHX) announced that the European Medicine Agency has decided that the design of its Phase 3 clinical trial, MASTERS-2, assessing its MultiStem cell therapy product in patients with ischemic stroke should be sufficient to support approval. The decision is in line with with the U.S. Special Protocol Assessment and Fast Track Designation. Scientific Advice is a procedure offered by EMA to stakeholders for clarification of questions arising during development of medicinal products.
The company stock reacted positively to the news and traded over 15 percent in its pre market session, trimming its 12 months loss to 31 percecnt.

Teva Pharmaceuticals Industries ($TEVA) announced receiving the FDA approval for its its QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol for the maintenance treatment of asthma in patients at least four years old. QVAR® RediHaler™ differs from conventional metered-dose inhalers (MDIs) as it delivers medication via a breath-actuated MDI, eliminating the need for hand-breath coordination during inhalation. The company plans to launch the product commercially by the first quarter of the coming year. QVAR is currently available as QVAR MDI with dose counter, which was approved by the FDA in 2014.
Teva stock is currently trading 43 percent down on Year to Date basis.


Imprimis Pharmaceuticals ($IMMY) stock plummeted as the company reported that the FDA is investigating two serious adverse events related to its curcumin emulsion for injection product. One of the incidents involved cardiac arrest.
LivaNova announced that its Perceval heart valve has been approved by the U.S. Centers for Medicare and Medicaid Services for n additional reimbursement payment to hospitals for implanting the device. The change will be effective from October 1.

Omeros ($OMER) announced receiving the Orphan Drug designation from the FDA for its lead drug candidate OMS721 for treating IgA nephropathy, a kidney disorder. The drug already has Breakthrough Therapy status for the condition.

Pfizer ($PFE) reported that the FDA’s Oncologic Drugs Advisory Committee will meet on September 19 to review and discuss the company's supplemental New Drug Application (sNDA) seeking approval for the use of SUTENT (sunitinib malate) as adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.


Amicus Therapeutics Ltd. ($FOLD) reported its revenue for the second quarter of the year at $7.2 million, up 71.4 percent sequentially. Its net loss stood at $48.1 million, or $0.34 per share, compared to a net loss of $51.1 million, or $0.40 per share, for the second quarter 2016. The company’s Cash, cash equivalents, and marketable securities totaled $227.2 million at June 30, 2017 compared to $330.4 million at December 31, 2016.
Eyegate Pharmaceuticals ($EYEG) announced that its revenue for the second quarter of 2017 was $0.148 million, compared with $0.235 million in the second quarter of 2016. Its net loss for the second quarter of 2017 was $3.3 million, compared with $3.8 million in the second quarter of 2016.

Brokerage Brokerage Ranking Action Company Rating Price Target Impact on Share Price Actions
Leerink Swann Login to View
Set Price Target AmerisourceBergen Corporation (Holding Co) (ABC)
Outperform -> Buy $100.00 -> $90.00 Low

Chardan Capital Login to View
Reiterates Arbutus Biopharma Corporation (ABUS)
Buy Low

Ladenburg Thalmann Financial Services Login to View
Initiates BeiGene (BGNE)
Buy $81.00 Low

Jefferies Group LLC Login to View
Reiterates Corium International (CORI)
Buy $10.00 Low

Jefferies Group LLC Login to View
Reiterates Aevi Genomic Medicine (GNMX)
Hold $1.50 Low

Canaccord Genuity Login to View
Upgrades Illumina (ILMN)
Hold -> Buy $170.00 -> $215.00 Low

Gainers (% price change) Last Trade Change Mkt Cap
Spectrum Pharmaceuticals
8.96 +1.63 (22.24%) 720.49M
Gen-Probe Incorporated
9.85 +1.59 (19.25%) 1.42B
Allscripts Healthcare
13.12 +1.45 (12.43%) 2.38B
PDL BioPharma Inc
2.39 +0.22 (10.14%) 384.75M
Pacific Biosciences of
4.01 +0.35 (9.56%) 436.93M
Losers (% price change)
Teva Pharmaceutical
20.60 -3.15 (-13.26%) 22.52B
Oclaro, Inc.
8.74 -0.75 (-7.90%) 1.46B
The Ensign Group, Inc.
20.13 -1.51 (-6.98%) 1.02B
Ironwood Pharmaceuticals
15.48 -1.16 (-6.97%) 2.30B
Bio-Rad Laboratories, Inc
227.31 -14.97 (-6.18%) 6.71B
Most Actives (dollar volume)
Teva Pharmaceutical
20.60 -3.15 (-13.26%) 22.52B
Gilead Sciences, Inc.
73.16 -1.21 (-1.63%) 95.60B
Pfizer Inc.
33.64 +0.21 (0.63%) 200.33B
UnitedHealth Group Inc
194.88 +0.11 (0.06%) 187.80B
Celgene Corporation
136.70 +0.80 (0.59%) 106.95B